27 May 2025 : Database Analysis
Glucagon-Like Peptide-1 Receptor Agonists Lead to Gastrointestinal Benefits in Patients with Type 2 Diabetes: A Real-World Study
Jung-Hui Hsu AEF 1, Hsueh-Fen Bai ADF 2, Mon-Ting Chen CD 3, Yu-Wei Fang AD 3,4,5, Jing-Tong Wang CE 3,4, Chieh-Yu Liu
DF 3, Ming-Hsein Tsai ADEF 3,4,5*
DOI: 10.12659/MSM.946935
Med Sci Monit 2025; 31:e946935
Figure 2 Kaplan-Meier cumulative event-free plots. Acute pancreatitis (A), biliary tract disease (B), liver failure (C), peritonitis (D), peptic ulcer (E), and GI bleeding (F) in the study population between GLP1-RA and DPP4i. Shaded areas indicate 95% confidence intervals. GLP1-RA – glucagon-like peptide receptor agonist; DPP4i – dipeptidyl peptidase 4 inhibitor; GI – gastrointestinal.